ArticleFrontiers in oncology2025
Molecular mechanism of LncRNA MALAT1 in regulating hepatocellular carcinoma progression via the miR-383-5p/PRKAG1 axis and its role in the tumor immune microenvironment.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The dual role of AMPK in cancer metabolic reprogramming.Molecular biology reports · 2026Review
- Decoding the functional landscape of long non-coding RNAs in hepatocellular carcinoma: molecular mechanisms, clinical implications, and therapeutic prospects.Journal of the Egyptian National Cancer Institute · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) is a highly prevalent malignant tumor worldwide, and its development is closely associated with dysregulated non-coding RNA expression. The long non-coding RNA MALAT1 is overexpressed in multiple cancers, but its precise mechanistic role and downstream regulatory network in HCC remain incompletely understood. Additionally, PRKAG1, a regulatory subunit of AMPK, has an unclear function in tumor progression. This study aimed to investigate the role and clinical significance of the MALAT1-PRKAG1 axis in HCC pathogenesis. Methods: A multi-omics approach was employed to systematically dissect the mechanism of the MALAT1-PRKAG1 axis in HCC. Bioinformatics analysis using GEPIA2 and TCGA databases revealed that MALAT1 and PRKAG1 were significantly upregulated in HCC and correlated with poor prognosis. Cellular experiments demonstrated that knockdown of MALAT1 or PRKAG1 suppressed HCC cell proliferation, migration, and invasion. Mechanistic studies indicated that MALAT1 upregulates PRKAG1 expression by competitively binding miR-383-5p. Further analyses showed that PRKAG1 remodels the tumor immune microenvironment by modulating immune cell infiltration (CIBERSORT analysis) and intercellular communication (single-cell RNA sequencing), while also activating key pathways such as the cell cycle and DNA repair (GO/KEGG enrichment analysis). Results: This study uncovered the critical role of the MALAT1-PRKAG1 regulatory axis in HCC. MALAT1 was significantly overexpressed in HCC tissues and cell lines, and its expression was associated with poor patient prognosis. Knockdown of MALAT1 markedly inhibited HCC cell proliferation, migration, and invasion. PRKAG1, as a downstream target of MALAT1, was also highly expressed in HCC and correlated with tumor stage and adverse outcomes. Mechanistically, MALAT1 competitively binds miR-383-5p to relieve its suppression of PRKAG1, thereby activating the P53 and AKT signaling pathways. Additionally, PRKAG1 modulated immune cell infiltration (particularly CD4+ T cells and M0 macrophages) and promoted intercellular communication via the MIF signaling network. Multi-omics analysis revealed that PRKAG1-associated genes were primarily enriched in critical pathways, including the cell cycle and DNA repair, collectively driving HCC progression. Conclusion: This study elucidates the oncogenic role of the MALAT1/miR-383-5p/PRKAG1 axis in HCC, demonstrating that PRKAG1 promotes tumor progression by regulating cell proliferation, the immune microenvironment, and key signaling pathways. These findings provide potential novel targets for HCC prognosis assessment and targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.